ZA200302821B - Transdermal electrotransport device and method for manufacturing same. - Google Patents
Transdermal electrotransport device and method for manufacturing same. Download PDFInfo
- Publication number
- ZA200302821B ZA200302821B ZA200302821A ZA200302821A ZA200302821B ZA 200302821 B ZA200302821 B ZA 200302821B ZA 200302821 A ZA200302821 A ZA 200302821A ZA 200302821 A ZA200302821 A ZA 200302821A ZA 200302821 B ZA200302821 B ZA 200302821B
- Authority
- ZA
- South Africa
- Prior art keywords
- housing
- ethylene
- approximately
- octene copolymer
- percent
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 25
- 238000012384 transportation and delivery Methods 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 claims description 11
- 238000001746 injection moulding Methods 0.000 claims description 9
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 7
- 229960002428 fentanyl Drugs 0.000 claims description 6
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical class C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims description 5
- 239000012491 analyte Substances 0.000 claims description 4
- 239000000155 melt Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 238000003856 thermoforming Methods 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 239000000463 material Substances 0.000 description 22
- 230000001070 adhesive effect Effects 0.000 description 15
- 239000000853 adhesive Substances 0.000 description 14
- 239000000017 hydrogel Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 238000012377 drug delivery Methods 0.000 description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 description 8
- 230000037317 transdermal delivery Effects 0.000 description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 description 7
- -1 general Chemical compound 0.000 description 7
- 238000010943 off-gassing Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000005260 corrosion Methods 0.000 description 6
- 230000007797 corrosion Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 229920001477 hydrophilic polymer Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004739 sufentanil Drugs 0.000 description 3
- 238000013271 transdermal drug delivery Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229960005455 polacrilin Drugs 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940005486 antimigraine preparations Drugs 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000013536 elastomeric material Substances 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920006112 polar polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Electrotherapy Devices (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Battery Electrode And Active Subsutance (AREA)
- Light Receiving Elements (AREA)
- Secondary Cells (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23189800P | 2000-09-11 | 2000-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200302821B true ZA200302821B (en) | 2004-10-11 |
Family
ID=22871065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200302821A ZA200302821B (en) | 2000-09-11 | 2003-04-10 | Transdermal electrotransport device and method for manufacturing same. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20020128591A1 (no) |
| EP (1) | EP1317306B1 (no) |
| JP (1) | JP4922537B2 (no) |
| KR (1) | KR100822339B1 (no) |
| CN (1) | CN1273143C (no) |
| AT (1) | ATE293475T1 (no) |
| AU (2) | AU9071901A (no) |
| CA (1) | CA2422017C (no) |
| DE (1) | DE60110245T2 (no) |
| ES (1) | ES2241871T3 (no) |
| HK (1) | HK1064314A1 (no) |
| HU (1) | HU225563B1 (no) |
| IL (2) | IL154838A0 (no) |
| MX (1) | MXPA03002177A (no) |
| NO (1) | NO20031098L (no) |
| NZ (1) | NZ524683A (no) |
| PT (1) | PT1317306E (no) |
| WO (1) | WO2002022204A2 (no) |
| ZA (1) | ZA200302821B (no) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
| US20090210032A1 (en) * | 2004-07-23 | 2009-08-20 | Ben Zion Beiski | Manufacturing methods, testing methods, and testers for intra-oral electronically embedded devices |
| DE602006004661D1 (de) * | 2005-09-21 | 2009-02-26 | Mitsubishi Chem Corp | Gestreckte Polyamidfilme |
| JP2007260082A (ja) * | 2006-03-28 | 2007-10-11 | Transcutaneous Technologies Inc | イオントフォレーシス装置 |
| EP2101864A2 (en) * | 2006-12-20 | 2009-09-23 | ALZA Corporation | Anode for electrotransport of cationic drug |
| US20080234627A1 (en) * | 2007-03-22 | 2008-09-25 | Wanda Dent | Pivotally engaged multiple part electrotransport drug delivery device |
| US20090105634A1 (en) * | 2007-10-17 | 2009-04-23 | Alza Corporation | Anodic Reservoir for Electrotransport of Cationic Drug |
| US20090105632A1 (en) * | 2007-10-18 | 2009-04-23 | Padmanabhan Rama V | Electrotransport Of Lisuride |
| WO2009073686A1 (en) * | 2007-12-03 | 2009-06-11 | Trans Dermal Patents Company, Llc | Agent delivery system and uses of the same |
| US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
| US8190252B2 (en) | 2009-02-12 | 2012-05-29 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
| US8903485B2 (en) | 2009-08-06 | 2014-12-02 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
| US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
| WO2011100376A2 (en) | 2010-02-10 | 2011-08-18 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
| KR101164779B1 (ko) | 2010-04-14 | 2012-07-10 | (주)휴레브 | 보행보조 일체형 전극패드 및 이를 이용한 보행보조 장치 |
| CN106955415B (zh) * | 2011-03-24 | 2019-06-18 | 因卡伯实验室有限责任公司 | 用于治疗剂的两阶段经皮离子电渗递送的系统及方法 |
| US8301238B2 (en) | 2011-03-31 | 2012-10-30 | Incline Therapeutics, Inc. | Two-part electrotransport device |
| US8428709B1 (en) | 2012-06-11 | 2013-04-23 | Incline Therapeutics, Inc. | Current control for electrotransport drug delivery |
| US8428708B1 (en) | 2012-05-21 | 2013-04-23 | Incline Therapeutics, Inc. | Self-test for analgesic product |
| US8781571B2 (en) | 2011-03-31 | 2014-07-15 | Incline Therapeutics, Inc. | Switch validation circuit and method |
| WO2012154704A2 (en) | 2011-05-06 | 2012-11-15 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
| USD712048S1 (en) * | 2013-01-23 | 2014-08-26 | Ossur Hf | Strap dosing system including a sleeve |
| CA3043987A1 (en) * | 2016-11-18 | 2018-05-24 | Norton (Waterford) Limited | Inhaler |
| US20200179262A1 (en) * | 2017-09-25 | 2020-06-11 | Dow Global Technologies Llc | Polyolefins as fragrance delivery vehicles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141359A (en) | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
| US5224928A (en) | 1983-08-18 | 1993-07-06 | Drug Delivery Systems Inc. | Mounting system for transdermal drug applicator |
| US5006108A (en) * | 1988-11-16 | 1991-04-09 | Noven Pharmaceuticals, Inc. | Apparatus for iontophoretic drug delivery |
| US5047007A (en) | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
| US5224927A (en) | 1990-11-01 | 1993-07-06 | Robert Tapper | Iontophoretic treatment system |
| US5254081A (en) | 1991-02-01 | 1993-10-19 | Empi, Inc. | Multiple site drug iontophoresis electronic device and method |
| US5246418A (en) | 1991-12-17 | 1993-09-21 | Becton Dickinson And Company | Iontophresis system having features for reducing skin irritation |
| US5246118A (en) * | 1992-07-17 | 1993-09-21 | Package Machinery Company | Method and apparatus for separating and sorting articles |
| US5264219A (en) * | 1992-08-07 | 1993-11-23 | Minnesota Mining And Manufacturing Company | Transdermal drug delivery backing |
| US5387189A (en) * | 1993-12-02 | 1995-02-07 | Alza Corporation | Electrotransport delivery device and method of making same |
| WO1998019259A1 (en) * | 1996-10-25 | 1998-05-07 | Ipf, Inc. | System and method for managing and serving consumer product related information over the internet |
| EP0766578B1 (en) * | 1994-06-24 | 2000-10-04 | Cygnus, Inc. | Iontophoretic sampling device |
| US5879322A (en) * | 1995-03-24 | 1999-03-09 | Alza Corporation | Self-contained transdermal drug delivery device |
| US5853383A (en) * | 1995-05-03 | 1998-12-29 | Alza Corporation | Preparation for formulations for electrotransport drug delivery |
| US6881208B1 (en) * | 1995-06-05 | 2005-04-19 | Joseph B. Phipps | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
| KR100270062B1 (ko) * | 1995-08-14 | 2000-11-01 | 나까도미 히로다카 | 이온토포레시스용 플라스터 구조체 |
| US5881743A (en) * | 1996-02-21 | 1999-03-16 | Nadel Industries | Co-molded makeup applicator assembly |
| ATE274973T1 (de) * | 1998-01-28 | 2004-09-15 | Alza Corp | Electrochemisch reaktive kathode für elektrotransport gerät |
| CN1170604C (zh) * | 1998-11-02 | 2004-10-13 | 阿尔萨公司 | 含有可相容的抗菌剂的电转运装置 |
| US6306518B1 (en) * | 1999-05-19 | 2001-10-23 | Montell Technology Company Bv | High surface gloss, co-extruded sheets from propylene polymer materials |
| US6255396B1 (en) * | 1999-09-09 | 2001-07-03 | Baxter International Inc. | Cycloolefin blends and method for solvent bonding polyolefins |
-
2001
- 2001-09-10 IL IL15483801A patent/IL154838A0/xx unknown
- 2001-09-10 AU AU9071901A patent/AU9071901A/xx active Pending
- 2001-09-10 HU HU0302609A patent/HU225563B1/hu not_active IP Right Cessation
- 2001-09-10 EP EP01970743A patent/EP1317306B1/en not_active Expired - Lifetime
- 2001-09-10 NZ NZ524683A patent/NZ524683A/en unknown
- 2001-09-10 AT AT01970743T patent/ATE293475T1/de not_active IP Right Cessation
- 2001-09-10 DE DE60110245T patent/DE60110245T2/de not_active Expired - Lifetime
- 2001-09-10 CA CA002422017A patent/CA2422017C/en not_active Expired - Fee Related
- 2001-09-10 MX MXPA03002177A patent/MXPA03002177A/es active IP Right Grant
- 2001-09-10 KR KR1020037003591A patent/KR100822339B1/ko not_active IP Right Cessation
- 2001-09-10 WO PCT/US2001/028258 patent/WO2002022204A2/en active IP Right Grant
- 2001-09-10 US US09/950,364 patent/US20020128591A1/en not_active Abandoned
- 2001-09-10 JP JP2002526449A patent/JP4922537B2/ja not_active Expired - Fee Related
- 2001-09-10 ES ES01970743T patent/ES2241871T3/es not_active Expired - Lifetime
- 2001-09-10 CN CNB018184936A patent/CN1273143C/zh not_active Expired - Fee Related
- 2001-09-10 AU AU2001290719A patent/AU2001290719B2/en not_active Ceased
- 2001-09-10 PT PT01970743T patent/PT1317306E/pt unknown
-
2003
- 2003-03-10 IL IL154838A patent/IL154838A/en not_active IP Right Cessation
- 2003-03-10 NO NO20031098A patent/NO20031098L/no not_active Application Discontinuation
- 2003-04-10 ZA ZA200302821A patent/ZA200302821B/en unknown
-
2004
- 2004-09-15 HK HK04107036A patent/HK1064314A1/xx not_active IP Right Cessation
-
2008
- 2008-10-07 US US12/246,579 patent/US20090036822A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20031098D0 (no) | 2003-03-10 |
| US20020128591A1 (en) | 2002-09-12 |
| HK1064314A1 (en) | 2005-01-28 |
| PT1317306E (pt) | 2005-06-30 |
| HU225563B1 (en) | 2007-03-28 |
| HUP0302609A3 (en) | 2006-01-30 |
| AU2001290719B2 (en) | 2006-06-22 |
| IL154838A0 (en) | 2003-10-31 |
| CN1273143C (zh) | 2006-09-06 |
| DE60110245T2 (de) | 2006-03-09 |
| AU9071901A (en) | 2002-03-26 |
| ES2241871T3 (es) | 2005-11-01 |
| KR20030070582A (ko) | 2003-08-30 |
| CN1496275A (zh) | 2004-05-12 |
| IL154838A (en) | 2010-11-30 |
| DE60110245D1 (de) | 2005-05-25 |
| NO20031098L (no) | 2003-05-07 |
| WO2002022204A2 (en) | 2002-03-21 |
| MXPA03002177A (es) | 2004-12-13 |
| KR100822339B1 (ko) | 2008-04-16 |
| NZ524683A (en) | 2005-02-25 |
| ATE293475T1 (de) | 2005-05-15 |
| CA2422017A1 (en) | 2002-03-21 |
| AU2001290719C1 (en) | 2002-03-26 |
| JP4922537B2 (ja) | 2012-04-25 |
| EP1317306B1 (en) | 2005-04-20 |
| HUP0302609A2 (hu) | 2003-11-28 |
| WO2002022204A3 (en) | 2002-06-13 |
| JP2004508148A (ja) | 2004-03-18 |
| CA2422017C (en) | 2009-11-24 |
| EP1317306A2 (en) | 2003-06-11 |
| US20090036822A1 (en) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1317306B1 (en) | Transdermal electrotransport device and method for manufacturing same | |
| AU2001290719A1 (en) | Transdermal electrotransport device and method for manufacturing same | |
| AU695465B2 (en) | Device for transdermal electrotransport delivery of fentanyl and sufentanil | |
| US6171294B1 (en) | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | |
| US6425892B2 (en) | Device for transdermal electrotransport delivery of fentanyl and sufentanil | |
| US6216033B1 (en) | Device for transdermal electrotransport delivery of fentanyl and sufentanil | |
| US20090264855A1 (en) | Method and Device for Transdermal Electrotransport Delivery of Fentanyl and Sufentanil |